vascuCAP vs PMcardio
AI Verdict
Choose vascuCAP if…
Choose vascuCAP (now ElucidVivo/PlaqueIQ) if you need a detailed, non-invasive assessment of cardiovascular risk based on plaque composition and morphology from CT angiography. This tool is ideal for optimizing treatment decisions and stratifying risk for stroke and heart attack by providing histologically-validated quantification of plaque components and 3D visualizations of arterial vessels.
View vascuCAP →Choose PMcardio if…
Choose PMcardio if you require rapid and accurate interpretation of ECGs for the immediate assessment of over 50 cardiac conditions, especially in acute care or emergency settings. This mobile and web-based platform is best suited for clinicians who need expert-level ECG analysis at the point of care, including detection of STEMI/OMI and reduced LVEF, to confidently guide quick clinical decisions.
View PMcardio →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers a mobile app and web platform, allowing for instant AI-powered ECG interpretations at the point of care, which suggests high accessibility and ease of use for various healthcare professionals. Elucid's vascuCAP, while providing 3D visualization, is primarily focused on CT angiography analysis, which typically involves more complex workflows and dedicated imaging workstations. PMcardio's freemium model also allows individual clinicians to try the app with 5 free ECG analyses per month, lowering the barrier to entry and promoting individual adoption.
Clinical Value
PMcardioPMcardio is clinically validated in over 25 studies and trusted by over 100,000 clinicians, detecting over 50 cardiac conditions with high accuracy, including early STEMI detection and reduced false alarms. Elucid's vascuCAP is FDA-cleared and histologically validated for plaque quantification and stroke risk prediction, demonstrating improved accuracy over stenosis-based methods. However, PMcardio's broader range of detectable conditions and extensive clinician adoption suggest a wider immediate clinical impact at the point of care.
Pricing & Value
PMcardioPMcardio offers a transparent freemium model with a free plan for 5 ECG analyses per month and a Pro Plan for unlimited use, making it accessible for individual clinicians and allowing them to experience its value before committing financially. Elucid's vascuCAP requires contacting for pricing, which suggests a less transparent and potentially higher entry cost, likely targeting enterprise-level deployments.
Enterprise Readiness
PMcardioPMcardio is designed for enterprise deployment, connecting to existing ECG systems, EHR/CVIS, and EMS systems, with robust security and compliance (SOC 2 Type II, ISO 27001, GDPR, HIPAA). It offers centralized report management and can scale across campuses and care settings. Elucid's vascuCAP also offers cloud and on-premise deployment and HIPAA compliance, but PMcardio's explicit focus on system-wide cardiac care coordination and extensive integrations demonstrate a more comprehensive enterprise readiness.
Innovation
PMcardioPMcardio features 'ECGxplainu2122' with visual AI explainability using heatmaps, which enhances trust and understanding of the AI's decisions, and 'Queen of Heartsu2122' for advanced STEMI/OMI detection. Elucid's vascuCAP offers histologically-validated plaque quantification and 3D visualization, which is innovative for non-invasive CT angiography analysis. However, PMcardio's explainable AI and its ability to detect a wider array of conditions from ECGs, a more readily available diagnostic, position it as highly innovative for point-of-care diagnostics.
Support & Docs
PMcardioPMcardio provides a Help Center with user-friendly tutorials and manuals, FAQs, and regulatory and security documentation readily available on its website. Elucid Bioimaging's documentation and support details are not as explicitly detailed or easily accessible through public information, suggesting PMcardio offers more transparent and comprehensive support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | vascuCAP | PMcardio |
|---|---|---|
| Tool Name | vascuCAP (now ElucidVivo/PlaqueIQ) | PMcardio |
| Company | Elucid Bioimaging | Powerful Medical |
| Description | FDA-cleared AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. | CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. |
| Regulatory Clearance | FDA-cleared | CE-certified |
| Key Functionality | AI-enabled CT angiogram analysis, histologically-validated plaque quantification and characterization, risk stratification for stroke and heart attack | Instant AI-powered ECG interpretations, detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), visual AI explainability with heatmaps |
| Specialties | Cardiology, Radiology, Vascular Surgery | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring vascuCAP and PMcardio.